Thalidomide combined with thanscatheter artierial chemoembolzation for primary hepatocellular carcinoma: A systematic review and meta-analysis

Oncotarget

Volumn 8, Issue 27, 2017, Pages 44976-44993

  Cao, De Dong ^a   Xu, Hui Lin ^b   Liu, Liang ^c   Zheng, Yong Fa ^a   Gao, Si Fa ^a   Xu, Xi Ming ^a   Ge, Wei ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b The Fifth Hospital of Wuhan   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Hepatocellular carcinoma; Meta analysis; Survival; TACE; Thalidomide

Indexed keywords

ALPHA FETOPROTEIN; THALIDOMIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ADULT; AGED; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CELLULAR IMMUNITY; CHEMOEMBOLIZATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIMARY TUMOR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; ADVERSE EVENT; LIVER TUMOR; MORTALITY; MULTIMODALITY CANCER THERAPY; ODDS RATIO; PROCEDURES; PUBLISHING; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNITY, CELLULAR; LIVER NEOPLASMS; ODDS RATIO; PUBLICATION BIAS; QUALITY OF LIFE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 85021845807     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16689     Document Type: Review

References (72)

1. Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. Gut Liver. 2016; 10:332-39.
2. Yuan P, Chen P, Qian Y. Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBVRelated Hepatocellular Carcinoma: An Updated Meta-Analysis. Can J Gastroenterol Hepatol. 2016; 2016: 5234969.
3. Chiou HE, Wang TE, Wang YY, Liu HW. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol. 2006; 12:6955-60. doi
4. Ch'ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol. 2015; 7:2029-40.
5. Bimonte S, Leongito M, Piccirillo M, de Angelis C, Pivonello C, Granata V, Izzo F. Radio-frequency ablationbased studies on VX2rabbit models for HCC treatment. Infect Agent Cancer. 2016; 11:38.
6. Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol. 2016; 8:607-15.
7. Zou JH, Zhang L, Ren ZG, Ye SL. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis. 2016; 17:510-17.
8. Guo W, He X, Li Z, Li Y. Combination of Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) vs. Surgical Resection (SR) on Survival Outcome of Early Hepatocellular Carcinoma: A Meta-Analysis. Hepatogastroenterology. 2015; 62:710-14.
9. Zhang L, Hu P, Chen X, Bie P. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One. 2014; 9:e100305.
10. Geschwind JF, Gholam PM, Goldenberg A, Mantry P, Martin RC, Piperdi B, Zigmont E, Imperial J, Babajanyan S, Foreman PK, Cohn A. Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry. Liver Cancer. 2016; 5:37-46.
11. Ranieri G, Ammendola M, Marech I, Laterza A, Abbate I, Oakley C, Vacca A, Sacco R, Gadaleta CD. Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients. World J Gastroenterol. 2015; 21:6018-25.
12. Wan X, Zhai X, Yan Z, Yang P, Li J, Wu D, Wang K, Xia Y, Shen F. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. Oncotarget. 2016; 7:83806-16. doi: 10.18632/oncotarget.11514
13. Ranieri G, Marech I, Lorusso V, Goffredo V, Paradiso A, Ribatti D, Gadaleta CD. Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol. 2014; 20:486-97.
14. Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: standards and Developments. Visc Med. 2016; 32:116-20.
15. Dmoszynska A, Podhorecka M, Manko J, Bojarska-Junak A, Rolinski J, Skomra D. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. Neoplasma. 2005; 52:175-81 doi
16. Feng N, Chen H, Fu S, Bian Z, Lin X, Yang L, Gao Y, Fang J, Ge Z. HIF-1a and HIF-2a induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide. Sci Rep. 2016; 6:27280.
17. Gao M, Kong Y, Wang H, Xie B, Yang G, Gao L, Zhang Y, Zhan F, Dai B, Tao Y, Shi J. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials. Tumour Biol. 2016; 37:11081-98.
18. Lyu WW, Zhao QC, Song DH, Zhang JJ, Ding ZX, Li BY, Wei CM. Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis. Chin Med J (Engl). 2016; 129:320-25.
19. Wu J, Ng J, Christos PJ, Goldenberg AS, Sparano J, Sung MW, Hochster HS, Muggia FM. Chronic thalidomide and chemoembolization for hepatocellular carcinoma. Oncologist. 2014; 19:1229-30.
20. Liu Y, He S, Ding Y, Huang J, Zhang Y, Chen L. The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis. Contemp Oncol (Pozn). 2014; 18:39-47.
21. Huang YT, Cheng CC, Chiu TH, Lai PC. Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer. Int J Oncol. 2015; 47:1711-24.
22. Wang-Yuan Z, Jiang-Zheng Z, Lu YD, Hao XB, Hong T, Huang F, Lei JH, He ZH, Huang MZ. Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma. Int J Hyperthermia. 2016; 32:193-98.
23. Liang PC, Ch'ang HJ, Hsu C, Chen LT, Shih TT, Liu TW. Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide. Hepatol Int. 2015; 9:258-68.
24. Nagy LI, Molnár E, Kanizsai I, Madácsi R, ózsvári B, Fehér LZ, Fábián G, Marton A, Vizler C, Ayaydin F, Kitajka K, Hackler L Jr, Mátés L, et al. Lipid droplet binding thalidomide analogs activate endoplasmic reticulum stress and suppress hepatocellular carcinoma in a chemically induced transgenic mouse model. Lipids Health Dis. 2013; 12:175.
25. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010; 116:4590-96.
26. Yau T, Chan P, Wong H, Ng KK, Chok SH, Cheung TT, Lam V, Epstein RJ, Fan ST, Poon RT. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology. 2007 (Suppl 1); 72:67-71.
27. Chuah B, Lim R, Boyer M, Ong AB, Wong SW, Kong HL, Millward M, Clarke S, Goh BC. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol. 2007; 46:234-38.
28. Hao MZ, Lin HL, Chen Q, Wu H, Yu WC, Chen TG. Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial. Chin J Cancer. 2007; 26:861-65.
29. Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology. 2003; 65: 242-9.
30. Weisheng Z, Qiang C, Yunbin Y, Hailan L, Mingzhi H, Wenchang Y, Kongzhi Z, Qizhong C. Influence of treatment of HCC with thalidomide in combination with TACE on Quality of life. CHINESE JOURNAL OF CLINICAL ONCOLOGY AND REHABILITATION. 2007: 478-80. doi:
31. Hai-lan L. Yun-bin HM-zZW-sY, Jian-xiong CQ-zCJ-bZ. The changes of vascular endothelial growth factor after treatment of thalidomide combined with TACE for HCC. Zhongguo Jieru Yingxiang Yu Zhiliaoxue. 2007:440-43.
32. Hao MZ, Lin HL, Chen Q, Wu H, Yu WC, Chen TG. [Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial]. Ai Zheng. 2007; 26:861-65.
33. Xiao-jun Q, Yu-dong J. Treatment of primary hepatic cancer by transcatheter hepatic artery chemoembolization therapy combined with thalidomide. Chinese Journal Of Cancer Prevention And Treatment. 2007: 788-9.
34. Xiu-fang L, Hai Z, Bing-sheng W, Jian-yu Z. Efficacy of combined thalidomide and interventional therapy in treatment of advanced hepatocellular carcinoma. Chinese Journal of Clinical Oncology And Rehabilitation. 2007; 546-7:50.
35. Long F, Wu-hua G, Lin L, Jian-bing W, Chun-ying X. The Preliminary Observation of the Therapeutic Effect of Transcather Arterial Chemoembolization Combined with Thalidomide on Advanced Hepatic Carcinoma. PRACTICAL CLINICAL MEDICINE. 2008; 29-30:4.
36. Chang-nan C, Qi-zuo P, Yun-xiao L, Ming-jun S, Huoxun H, Jia-kang Z, Miao-wen Z, Jin-song Y. Effect of thalidomide combined with TACE on recurrence and survival of primary liver cancer. China Trop Med. 2008:406-08.
37. Cheng Z, Changnan C, Yunxiao L, Mingjun S, Zhijian L, Qizuo P, Bingzhao L, Chanjuan C, Tingjie R, Feng X. Clinical effect of transcatheter arterial chemoembolization combined with gimeracil and oteracil potassium and thalidomide in treatment of advanced hepatocellular carcinoma. Journal of Modern Oncology. 2015; 2475-8.
38. xiao-bing Y, Xing-long H, Xiang S, Shi-wu Y, Chengfa L, Man M. Clinical research on advanced primary carcinoma of liver treated with transcatheter arterial chemoembolization combined Thalidomide. Anhui Medical and Pharmaceutical Journal. 2009: 1270-2.
39. Wei-min W, Shi-wu Y, Xiang S, Cheng-fa L, Ma M, Xiaobing Y, Meng-qin H, Rong-jie Y, Ying-xing C. Clinical research on middle-high dose Thalidomide Combined TACE treatment of primary liver cancer. Anhui Medical Journal. 2009: 1419-22.
40. Yun-xiao L, Chan-nan C, Qi-zuo P, Huo-xun Z. The Combination of Thalidomide with Transcatheter Arterial Chemoembolization in Treating Primary Liver Cancer. Journal of Gannan Medical University. 2010: 44-5.
41. Zenghu Z, Xiufang L, Ruiliang D, quanfu N. Clinical study of TACE combined with thalidomide and traditional Chinese medicine in patients with intermediate or advanced HCC. Journal of Emergency in Traditional Chinese Medicine. 2010: 1492-3.
42. Haiying J, Xiaodong X, Mei Z. The Analyses of Efficacy of Thalidomide Combined with Transcatheter Arterial Chemoembolization of Advanced Hepatocellular Carcinoma. JOURNAL OF BASIC AND CLINICAL ONCOLOGY. 2010: 226-8.
43. Fei W. Therapeutic effect of thalidomide plus TACE for patients with intermediate or advanced primary hepatocellular carcinoma. Guide of China medicine. 2010: 228-9.
44. Hai-ying J, Xiao-dong X, Mei Z. Combination of thalidomide and transcatheter arterial chemoembolization for advanced hepatocellular carcinoma. China J Cancer Prev Treat. 2011; 871-3:81.
45. Yan S, Hui-bin CM-cJ, Xue-ming X, Shu-xun L. Clinical study of transcatheter arterial chemoembolization combined with thalidomide on advanced hepatic carcinoma. Chinese Journal of Cancer Prevention and Treatment. 2011: 1043-5.
46. Jiqun P, Bai LGS, Bingshan X, Xiaomei L, Zhijian Y. Efficacy of the regimen of transcatheter arterial chemoembolization sequential thalidomide in advanced hepatocellular carcinoma. Journal of Modern Oncology. 2013: 811-3.
47. Zhenkai Y, Yaozhen L, Yan LJC. Effect of advanced hepatocellular carcinoma treated by conformal radiotherapy after thalidomide combined with trancather arterial chemoembolization. Journal of Modern Oncology. 2013: 2276-9.
48. Xia Z, Guangping L, Jiqun P. Effect of thalidomide combined with TACE on T lymphocytes and erythrocyte immune function of primary liver cancer. Shandong Yiyao. 2015: 70-72.
49. Lu Xd, Zhang Dr, Huang Xz. Clinical observation of efficacy of thalidomide combined with TACE for patients with intermediate or advanced stage primary hepatocellular carcinoma. Jiangsu Med J. 2014: 95-6.
50. Kang Z, Mengguo H, Zhixiang W. Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis. J Clin Hepatol. 2016: 899-903.
51. Xie D, Zhang L, Zhang J, Xie X, Yin X, Xue T, Chen R, Wang Y, Zhang B, Ren Z. (2015). Randomized controlled trial of thalidomide combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an interim analysis. National Liver Cancer Conference pp. 71.
52. Weisheng Z, Qiang C, Yunbin Y, Hailan L, Mingzhi H, Wenchang Y, Kongzhi Z, Qizhong C. The Changes of Cellular Immunity Function After Treatment of Thalidomide Combined with TACE for HCC. JOURNAL OF BASIC AND CLINICAL ONCOLOGY. 2007: 145-7. doi:
53. Yun-xiao L, Chan-nan C, Qi-zuo P, Huo-xun H. The Combination of Thalidomide with Transcatheter Arterial Chemoembolization in Treating Primary Liver Cancer. JOURNAL OF GANNAN MEDICAL UNIVERSITY. 2009: 176-7.
54. Hailan L, Zhenhua Z, Mingzhi H, Qiang C, Hui W, Wenchang Y, Kongzhi Z, Qizhong C. The impact of thalidomide on the disease progression time after TACE in patients with primary heaptocellular carcinoma. Fujian Med J. 2007:14-16.
55. Huang H, Zhou L, Peng L, Fu W, Zhang C, Hou J. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials. Leuk Res. 2014; 38:1048-54.
56. Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, Nagler A, Avigdor A. Bortezomib-cyclophosphamidedexamethasone (VCD) versus bortezomib-thalidomidedexamethasone (VTD)-based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Br J Haematol. 2014; 166:702-10.
57. Wang L, Xu YL, Zhang XQ. Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials. Leuk Lymphoma. 2014; 55:1479-88.
58. Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013; 98:87-94.
59. Kagoya Y, Nannya Y, Kurokawa M. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res. 2012; 36:1016-21.
60. Wang L, Cui J, Liu L, Sheng Z. Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis. Hematol Oncol. 2012; 30:163-69.
61. Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, et al, and National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012; 119:7-15.
62. Adlard JW. Thalidomide in the treatment of cancer. Anticancer Drugs. 2000; 11:787-91.
63. Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X, Han G. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One. 2014; 9:e91124.
64. Fu QH, Zhang Q, Bai XL, Hu QD, Su W, Chen YW, Su RG, Liang TB. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014; 140:1429-40.
65. Yang M, Yuan JQ, Bai M, Han GH. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Mol Biol Rep. 2014; 41:6575-82.
66. Demeria D, Birchall I, Bain VG. Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy. Can J Gastroenterol. 2007; 21:517-18.
67. Chen LT, Liu TW, Chao Y, Shiah HS, Chang JY, Juang SH, Chen SC, Chuang TR, Chin YH, Whang-Peng J. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2005; 22:217-26.
68. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology. 2015; 149: 1226-39 e4.
69. Tirumani SH, Fairchild A, Krajewski KM, Nishino M, Howard SA, Baheti AD, Rosenthal MH, Jagannathan JP, Shinagare AB, Ramaiya NH. Anti-VEGF molecular targeted therapies in common solid malignancies: comprehensive update for radiologists. Radiographics. 2015; 35:455-74.
70. Cao G, Li X, Qin C, Li J. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis. Med Sci Monit. 2015; 21:3144-51.
71. Matsui D, Nagai H, Mukozu T, Ogino YU, Sumino Y. VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy. Anticancer Res. 2015; 35:2205-10.
72. Tsurusaki M, Murakami T. Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer. 2015; 4:165-75.